PDL BioPharma, Inc. (PDLI) Reaches $2.49 After 8.00% Down Move; Last Week Canadian Natural Resources Limited (CNQ) Coverage

February 23, 2018 - By Peter Erickson

Among 14 analysts covering Canadian Natural Resources Limited (NYSE:CNQ), 10 have Buy rating, 0 Sell and 4 Hold. Therefore 71% are positive. Canadian Natural Resources Limited had 31 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 19 by Bank of America. The firm has “Sector Outperform” rating by Scotia Capital given on Friday, August 7. Morgan Stanley maintained it with “Overweight” rating and $52 target in Friday, October 13 report. The firm earned “Market Perform” rating on Wednesday, February 7 by Wells Fargo. The stock of Canadian Natural Resources Limited (NYSE:CNQ) has “Neutral” rating given on Monday, September 14 by Citigroup. The rating was downgraded by Morgan Stanley on Tuesday, January 12 to “Equal-Weight”. The stock has “Outperform” rating by Macquarie Research on Friday, August 5. RBC Capital Markets maintained it with “Outperform” rating and $39 target in Friday, November 6 report. The stock of Canadian Natural Resources Limited (NYSE:CNQ) has “Buy” rating given on Thursday, June 16 by RBC Capital Markets. The stock of Canadian Natural Resources Limited (NYSE:CNQ) earned “Neutral” rating by Macquarie Research on Friday, January 8. See Canadian Natural Resources Limited (NYSE:CNQ) latest ratings:

07/02/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
24/01/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $52 New Target: $58 Maintain
13/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $46 New Target: $52 Maintain

The stock of PDL BioPharma, Inc. (NASDAQ:PDLI) is a huge mover today! The stock decreased 0.60% or $0.015 during the last trading session, reaching $2.485. About 203,139 shares traded. PDL BioPharma, Inc. (NASDAQ:PDLI) has declined 26.03% since February 23, 2017 and is downtrending. It has underperformed by 42.73% the S&P500.The move comes after 8 months negative chart setup for the $383.53M company. It was reported on Feb, 23 by Barchart.com. We have $2.29 PT which if reached, will make NASDAQ:PDLI worth $30.68M less.

Analysts await PDL BioPharma, Inc. (NASDAQ:PDLI) to report earnings on March, 8 after the close. PDLI’s profit will be $4.63M for 20.71 P/E if the $0.03 EPS becomes a reality. After $0.14 actual earnings per share reported by PDL BioPharma, Inc. for the previous quarter, Wall Street now forecasts -78.57% negative EPS growth.

Investors sentiment increased to 1.5 in Q3 2017. Its up 0.70, from 0.8 in 2017Q2. It improved, as 13 investors sold PDL BioPharma, Inc. shares while 41 reduced holdings. 27 funds opened positions while 54 raised stakes. 131.24 million shares or 5.90% more from 123.93 million shares in 2017Q2 were reported. Wellington Management Grp Inc Llp holds 0% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 1.46M shares. Barclays Public Ltd Company holds 31,499 shares or 0% of its portfolio. Grp One Trading Limited Partnership owns 8,311 shares. Nationwide Fund Advsrs invested 0% in PDL BioPharma, Inc. (NASDAQ:PDLI). Brandes Ptnrs Lp holds 0.06% or 1.11 million shares in its portfolio. Mckinley Capital Mngmt Ltd Liability Delaware holds 0.05% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 328,619 shares. Robeco Institutional Asset Bv holds 0.02% or 1.02M shares in its portfolio. Ifrah Fincl Svcs Incorporated reported 0.06% in PDL BioPharma, Inc. (NASDAQ:PDLI). Millennium Ltd Llc holds 0.02% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 3.52M shares. The New York-based New York State Common Retirement Fund has invested 0% in PDL BioPharma, Inc. (NASDAQ:PDLI). Proshare Limited Liability Corporation holds 98,858 shares or 0% of its portfolio. Oppenheimer And reported 15,188 shares stake. Renaissance Techs Lc has 0.04% invested in PDL BioPharma, Inc. (NASDAQ:PDLI). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 9,162 shares in its portfolio. Architects holds 0% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 500 shares.

Among 4 analysts covering PDL BioPharma (NASDAQ:PDLI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. PDL BioPharma had 9 analyst reports since October 16, 2015 according to SRatingsIntel. RBC Capital Markets maintained PDL BioPharma, Inc. (NASDAQ:PDLI) on Friday, October 16 with “Sector Perform” rating. As per Thursday, October 26, the company rating was maintained by Cowen & Co. The firm has “Sector Perform” rating given on Tuesday, February 23 by RBC Capital Markets. Cowen & Co maintained the stock with “Hold” rating in Friday, August 4 report. The rating was maintained by RBC Capital Markets on Thursday, November 5 with “Sector Perform”. The stock of PDL BioPharma, Inc. (NASDAQ:PDLI) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, February 2. PiperJaffray maintained it with “Overweight” rating and $4 target in Thursday, December 22 report. Piper Jaffray maintained PDL BioPharma, Inc. (NASDAQ:PDLI) on Friday, November 3 with “Buy” rating.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $383.53 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It has a 5.05 P/E ratio. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>